Application of pregnenolone as active ingredient in preparation of medicine for treating psoriasis or atopic dermatitis

By using pregnenolone as the active ingredient, combined with appropriate excipients, the problem of insufficient treatment of psoriasis and atopic dermatitis in the prior art has been solved, significant therapeutic effects and low side effects have been achieved, and A new and effective treatment plan.

CN118924767AActive Publication Date: 2024-11-12XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202411005144.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-12
Estimated Expiration
2044-07-25

AI Technical Summary

Technical Problem

In the prior art, there are fewer drugs for the treatment of psoriasis and atopic dermatitis, and the efficacy is poor, and there is a lack of effective treatment options.

Method used

Pregnenolone is used as an active ingredient and combined with pharmaceutically acceptable excipients to prepare injectable, oral or topical drugs for the treatment of psoriasis and atopic dermatitis. The mass percentage of pregnenolone is not less than 0.5 %, and use different dosage forms and excipient combinations to improve therapeutic effect.

Benefits of technology

Pregnenolone significantly alleviates the phenotype of the mouse model of psoriasis and atopic dermatitis, has obvious efficacy, both effective in both systemic administration and topical use, with fewer side effects, reducing R&D and manufacturing costs, and has a wide range of Application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924767A_ABST
    Figure CN118924767A_ABST
Patent Text Reader

Abstract

The invention provides an application of pregnenolone as an active component in preparation of a medicine for treating psoriasis and atopic dermatitis. Researchers firstly find and prove that the pregnenolone can effectively relieve the phenotype of a psoriasis mouse model and the phenotype of an atopic dermatitis mouse model through long-term research, and has a remarkable treatment effect on psoriasis and atopic dermatitis. And the research shows that the pregnenolone has an obvious drug effect on treating psoriasis and atopic dermatitis no matter whether the pregnenolone is systematically administered or used as an external drug, has a wide application prospect and has a relatively high popularization and application value. As pregnenolone is a component originally contained in a mammal body, the pregnenolone has small side effects on a human body, and the research and development cost and the manufacturing cost are also reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of skin disease treatment, and in particular to an application of pregnenolone as an active ingredient in the preparation of a therapeutic drug for psoriasis or atopic dermatitis. Background Art

[0002] Psoriasis is a common immune-mediated chronic, recurrent skin disease, clinically manifested by erythema or scaling, localized or widespread. Its histopathology is specific, manifested by excessive proliferation of epidermal keratinocytes, hyperkeratosis with parakeratosis, acanthosis, and sparse inflammatory cell infiltration around the blood vessels in the superficial dermis. The incidence of psoriasis in the natural population is 0.1% to 3%, and its pathogenesis is complex and prone to recurrence.

[0003] Atopic dermatitis, also known as atopic dermatitis, atopic eczema, and hereditary allergic dermatitis, is a chronic recurrent skin inflammatory disease characterized by dry skin, itching, and eczematous rashes. The cause of this disease is still unclear. It is currently believed that the occurrence of this disease is closely related to the following causes: Genetic factors: Genetic factors can affect the barrier function and immune function of the skin. If there is a history of allergic diseases in family members, the probability of suffering from this disease will increase significantly; Immune abnormalities: Many immune cells and the cytokines, chemokines, and pro-inflammatory molecules they produce can participate in the onset of the disease; Abnormal skin barrier function: Damage to the skin barrier function can cause increased skin permeability and excessive water loss through the skin surface, leading to dry and flaky skin, and viruses or allergens can easily enter the body, inducing or aggravating immune and inflammatory responses.

[0004] At present, there are still few drugs for treating the above-mentioned skin diseases, so it is of great significance to find a new drug with good efficacy. Summary of the invention

[0005] Based on this, the present invention provides a use of pregnenolone as an active ingredient in the preparation of a therapeutic drug for psoriasis or atopic dermatitis.

[0006] The present invention also provides a therapeutic drug for psoriasis or atopic dermatitis, comprising pregnenolone as an active ingredient and pharmaceutically acceptable excipients.

[0007] In one embodiment, the therapeutic drug is an injectable drug, an oral drug or an externally applied drug.

[0008] In one embodiment, the mass percentage of pregnenolone in the therapeutic drug is not less than 0.5%.

[0009] In one embodiment, the therapeutic drug is in the form of an injection, a gel, a lotion, an ointment, a tincture, an oil, an ointment, a paste, a patch or a film.

[0010] In one embodiment, the excipient is selected from one or more of a solvent, a propellant, an emulsifier, a colorant, a binder, a disintegrant, a filler, a lubricant, a wetting agent, a stabilizer, a flavoring agent, a preservative, a fragrance, a penetration enhancer, a pH adjuster and a plasticizer.

[0011] In one embodiment, the solvent is selected from one or more of ethanol and saline.

[0012] In one embodiment, the preservative is selected from one or more of sorbic acid, methyl sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzyl parahydroxybenzoate, sodium methyl parahydroxybenzoate, benzoic acid and benzyl alcohol.

[0013] In one embodiment, the emulsifier is selected from one or more of polyoxyethylene hydrogenated castor oil, hydrogenated soybean lecithin, lanolin, glyceryl stearate, sorbitan sesquioleate, cetyl alcohol, stearyl alcohol, cetearyl alcohol, castor oil and palmitate.

[0014] The above solution of the present invention has the following beneficial effects:

[0015] Through long-term research, the researchers of the present invention first discovered and proved that pregnenolone can effectively alleviate the phenotype of psoriasis mouse model and the phenotype of atopic dermatitis mouse model, and has a significant therapeutic effect on psoriasis and atopic dermatitis. The present invention provides a new use for pregnenolone and provides a new drug for treating psoriasis and atopic dermatitis. Studies have shown that pregnenolone has obvious efficacy for treating psoriasis and atopic dermatitis, whether it is systemically administered or used as an external medicine, and has a wide range of application prospects and great promotion and application value. Moreover, since pregnenolone is a component already contained in mammals, it has little side effects on the human body, and also reduces research and development costs and manufacturing costs. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 These are photos of skin lesions on the backs of mice in groups 1 to 8 in Example 1 of the present invention;

[0017] Figure 2 The PASI score chart of the back skin lesions of mice in groups 1 to 8 in Example 1 of the present invention from the first day to the sixth day;

[0018] Figure 3 The PASI scores of the back skin lesions of the mice in groups 1 to 8 in Example 1 of the present invention on the sixth day;

[0019] Figure 4 HE staining micrographs of the skin lesions on the back of mice in groups 1 to 8 in Example 1 of the present invention on the sixth day;

[0020] Figure 5 These are photos of skin lesions on the backs of mice in groups 1 to 8 in Example 2 of the present invention;

[0021] Figure 6 The PASI score chart of the back skin lesions of mice in groups 1 to 8 in Example 2 of the present invention from the first day to the sixth day;

[0022] Figure 7 The PASI scores of the back skin lesions of the mice in groups 1 to 8 in Example 2 of the present invention on the sixth day;

[0023] Figure 8 HE staining micrographs of the skin lesions on the back of mice in groups 1 to 8 in Example 2 of the present invention on the sixth day;

[0024] Fig. 9 These are photos of ear lesions of mice in groups 1 to 8 in Example 3 of the present invention;

[0025] Fig.10 This is a graph showing the thickness change of ear skin lesions of mice in groups 1 to 8 from the first day to the ninth day in Example 3 of the present invention;

[0026] Fig.11 is the thickness of the ear skin lesions of mice in groups 1 to 8 on the ninth day in Example 3 of the present invention;

[0027] Fig.12 This is a HE staining micrograph of the ear skin lesions of mice in groups 1 to 8 in Example 3 of the present invention on the ninth day;

[0028] Fig.13 These are photos of ear lesions of mice in groups 1 to 8 in Example 4 of the present invention;

[0029] Fig.14 This is a thickness graph of ear skin lesions of mice in groups 1 to 8 from the first day to the ninth day in Example 4 of the present invention;

[0030] Fig.15 is the thickness of the ear skin lesions of mice in groups 1 to 8 in Example 4 of the present invention on the ninth day;

[0031] Fig.16 This is a HE staining micrograph of the ear skin lesions of mice in groups 1 to 8 in Example 4 of the present invention on the ninth day. DETAILED DESCRIPTION

[0032] In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following will be described in detail with reference to the accompanying drawings and specific embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] In addition, the technical features involved in the different embodiments of the present invention described below can be combined with each other as long as they do not conflict with each other. The reagents and instruments used in the examples are conventionally selected in the art unless otherwise specified. The experimental methods without specific conditions in the examples are implemented according to conventional conditions, such as the conditions described in the literature, books or methods recommended by the manufacturer.

[0034] the term

[0035] The PASI score (Psoriasis Area and Severity Index) is a comprehensive score for psoriasis patients based on the severity and area of ​​skin lesions. The final score is calculated using a specific formula and is often used to assess the severity of psoriasis vulgaris. It is an internationally accepted scoring standard for the severity of psoriasis skin lesions.

[0036] HE staining is hematoxylin-eosin staining, also known as HE staining, which is one of the commonly used staining methods in paraffin section technology. Hematoxylin staining solution is alkaline, which mainly makes the chromatin in the cell nucleus and the nucleic acid in the cytoplasm purple-blue; eosin is an acidic dye, which mainly makes the components in the cytoplasm and extracellular matrix red. HE staining is the most basic and widely used technical method in the teaching and scientific research of histology, embryology, and pathology.

[0037] "Pharmaceutically acceptable excipients" refer to those pharmaceutical excipients that are appropriate for administration to a patient within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0038] An embodiment of the present invention provides a use of pregnenolone as an active ingredient in the preparation of a therapeutic drug for psoriasis or atopic dermatitis.

[0039] Pregnenolone is an endogenous steroid hormone and a precursor of progesterone, mineralocorticoid, glucocorticoid, androgen, estrogen and neuroactive steroids. Pregnenolone is mainly synthesized in the adrenal glands, brain and gonads (testes and ovaries). Currently, its use as an active ingredient in the treatment of psoriasis and atopic dermatitis has not been recorded. The inventors have proved that pregnenolone is in an important position in the pathological pathways regulating psoriasis and atopic dermatitis through systematic mechanism exploration and verification, which is an important research conclusion based on the inventors' systematic scientific research. The content of the present invention is that pregnenolone and its oral dosage form, injection dosage form, and topical dosage form are all verified for the first time, which can effectively relieve psoriasis and atopic dermatitis.

[0040] A therapeutic drug for psoriasis or atopic dermatitis according to an embodiment of the present invention comprises pregnenolone as an active ingredient and pharmaceutically acceptable excipients.

[0041] In a specific example, the therapeutic drug is an injectable drug, an oral drug, or an externally applied drug, all of which can exert a therapeutic effect.

[0042] In a specific example, the mass percentage of pregnenolone in the therapeutic drug is not less than 0.5%. Optionally, the mass percentage of pregnenolone in the therapeutic drug is 0.5% to 99%, 0.5% to 50%, etc. It is understood that the specific concentration can be adjusted as needed according to the condition or individual situation, such as 0.5%, 1.0%, etc., without limitation thereto.

[0043] In a specific example, the dosage form of the therapeutic drug is an injection, a gel, a lotion, an ointment, a tincture, an oil, an ointment, a paste, a patch or a film, etc., which can be adjusted as needed.

[0044] In a specific example, the excipient is selected from one or more of a solvent, a propellant, an emulsifier, a colorant, an adhesive, a disintegrant, a filler, a lubricant, a wetting agent, a stabilizer, a flavoring agent, a preservative, a fragrance, a penetration enhancer, a pH regulator, and a plasticizer. It is understood that different excipients can be selected for use in combination according to the needs of the preparation of the dosage form.

[0045] In a specific example, the solvent is selected from one or more of ethanol and physiological saline, for example, dissolved in physiological saline to prepare an injection, etc.

[0046] Optionally, the preservative is selected from one or more of sorbic acid, methyl sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzyl parahydroxybenzoate, sodium methyl parahydroxybenzoate, benzoic acid and benzyl alcohol.

[0047] Optionally, the emulsifier is selected from one or more of polyoxyethylene hydrogenated castor oil, hydrogenated soybean lecithin, lanolin, glyceryl stearate, sorbitan sesquioleate, cetyl alcohol, stearyl alcohol, cetearyl alcohol, castor oil and palmitic acid ester.

[0048] Optionally, the disintegrant is selected from one or more of cross-linked sodium carboxymethylcellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone or low-substituted hydroxypropyl cellulose. Optionally, the colorant is selected from one or more of carbon black, iron black, iron brown, iron red and titanium dioxide.

[0049] The following are specific embodiments.

[0050] Example 1 Systemic administration of pregnenolone can significantly inhibit psoriasis

[0051] 1. Experimental methods

[0052] Forty-eight 8-week-old female Balb / c mice were randomly divided into 8 groups (6 mice in each group):

[0053] OVX group: Under isoflurane gas anesthesia, all mice except the sham control group underwent bilateral ovariectomy to remove the ovaries.

[0054] Sham control group: underwent surgery but without oophorectomy.

[0055] Pregnenolone (Preg) was purchased from Selleck, dissolved in ethanol and further diluted in sterile water to a working concentration before use.

[0056] Psoriasis IMQ modeling: The back was shaved in an area of ​​2.5 cm × 3.5 cm, and 62.5 mg of imiquimod (IMQ) was applied daily.

[0057] The treatment of mice in each group is shown in the following table:

[0058]

[0059] Groups 1 to 4 were not treated with external IMQ, group 5 was a sham operation group (simultaneously injected with sterile water + externally applied with IMQ to establish psoriasis-like dermatitis model); group 6 was an OVX group (simultaneously injected with sterile water + externally applied with IMQ); group 7 was an OVX group (simultaneously injected with low-dose Preg + externally applied with IMQ); group 8 was an OVX group (simultaneously injected with high-dose Preg + externally applied with IMQ); after continuous application of the drug for 5 to 7 days, the psoriasis lesion area and severity index (PASI) was scored on the back lesions of the mice to examine the psoriasis-like symptoms of the mice. Then the mice were weighed and photographed, and then the mice were killed, and the back lesions were taken for HE staining to examine the thickness of the epidermis, that is, the proliferation of keratinocytes, and the spleen of the mice was weighed and photographed.

[0060] The PASI scoring principle is as follows: daily assessment of the severity of skin inflammation, including measurement of skin thickness, crusting, and erythema. Scoring is performed using a 5-point scale (0-4):

[0061] Skin thickness (infiltration): 0: smooth skin without wrinkles; 1: slight wrinkles appear at the edge of the applied area; 2: slight wrinkles appear in the entire applied area; 3: the wrinkles in the applied area are further deepened; 4: based on the score of 3, the mouse has weight loss or poor condition;

[0062] Scaling: 0: smooth skin without scaling; 1: slight scaling of the skin in the applied area; 2: the skin in the applied area is completely covered with scaling; 3: the scaling in the applied area is further deepened; 4: based on the score of 3, the mouse has weight loss or poor condition;

[0063] Erythema: 0: smooth skin; 1: slight redness in the skin of the applied area; 2: the skin of the applied area turns completely red; 3: the redness of the applied area deepens further; 4: based on the score of 3, the mouse loses weight or is in poor condition;

[0064] Total score: the sum of the three scores of skin thickness, crusting and erythema.

[0065] 2. Results

[0066] like Figure 1 The photos of the back skin lesions of mice in groups 1 to 8 are shown. It can be seen that the back skin lesions in the IMQ group have obvious erythema, thickening, and scaling compared with the non-IMQ group, proving that the psoriasis model was successfully induced. In addition, the back skin lesions in the OVX+IMQ group were more severely inflamed than those in the sham surgery+IMQ group, indicating that postmenopausal sex hormone deficiency can aggravate psoriasis. In the OVX+injection group, the erythema, infiltration, and thickening of the Preg injection group were significantly reduced compared with the sterile water injection group, indicating that Preg can effectively treat psoriasis; the intra-group comparison of the Preg group showed that the high-dose Preg (10 mg / kg / d) had lighter skin lesions than the low-dose Preg (1 mg / kg / d), indicating that the higher the dose of Preg, the better the effect of inhibiting IMQ-induced psoriasis inflammation. In short, systemic administration of Preg can significantly inhibit postmenopausal IMQ-induced psoriasis-like inflammation.

[0067] like Figure 2 The PASI scores of the back skin lesions of mice in groups 1 to 8 from the first to sixth day are shown. Figure 3 Shown are the PASI scores of the back skin lesions of mice in groups 1 to 8 on the sixth day. It can be seen that systemic administration of Preg can effectively treat psoriasis, and the higher the dose, the better the effect.

[0068] like Figure 4 Shown are HE-stained micrographs of the back lesions of mice in groups 1 to 8 on the sixth day, further demonstrating that systemic administration of Preg can significantly and effectively improve psoriasis lesions.

[0069] Example 2 Topical administration of pregnenolone can significantly inhibit psoriasis

[0070] 1. Experimental methods

[0071] Forty 8-week-old female Balb / c mice were randomly divided into 8 groups (5 mice in each group), as shown in the following table:

[0072] Group Sham operation group Group OVX group 1 Sham operation group + IMQ 5 OVX group + IMQ 2 Sham operation group + IMQ + BASE 6 OVX surgery group + IMQ + BASE 3 Sham operation group + IMQ + 0.5% Preg 7 OVX group + IMQ + 0.5% Preg 4 Sham operation group + IMQ + 1.0% Preg 8 OVX group + IMQ + 1.0% Preg

[0073] Pregnenolone (Preg) was purchased from Selleck Company, dissolved in ethanol, and then prepared into gel preparations with mass concentrations of 0.5% and 1.0%. The Base group was the blank matrix group.

[0074] Psoriasis IMQ modeling: The back was shaved in an area of ​​2.5 cm × 3.5 cm, and 62.5 mg of imiquimod (IMQ) was applied daily.

[0075] Groups 1 to 4 were treated with sham surgery, and groups 5 to 8 were treated with OVX surgery. Psoriatic dermatitis modeling began 7 weeks after surgery. Groups 1 to 8 were given 62.5 mg / day of imiquimod topical in the morning. Groups 2 and 6 were given 62.5 mg of blank matrix 4 to 6 hours later. Groups 3 and 7 were given 0.5% Preg gel, and groups 4 and 8 were given 1.0% Preg gel. After 5 to 7 days of modeling, the psoriasis area and severity index (PASI) score was performed on the back lesions of the mice to examine the psoriasis-like symptoms of the mice. Then the mice were weighed and photographed, and then the mice were killed. The back lesions were taken for HE staining experiments to examine the thickness of the epidermis, that is, the proliferation of keratinocytes, and the spleen of the mice was weighed and photographed.

[0076] 2. Results

[0077] like Figure 5 The photos of the back lesions of mice in groups 1 to 8 are shown. It can be seen that the IMQ group has obvious erythema, thickening, and scaling, proving that the psoriasis model was successfully induced. Regardless of whether OVX surgery was performed, there was no significant difference in the lesions between the IMQ+topical BASE group and the IMQ group, indicating that the pure gel has no significant therapeutic effect on psoriasis. After adding Preg, the lesions in the IMQ+Preg group improved significantly, and the higher the concentration of Preg, the better the therapeutic effect. In addition, the effect of Preg in the OVX group was more significant.

[0078] like Figure 6 The PASI scores of the back skin lesions of mice in groups 1 to 8 from the first to sixth day are shown. Figure 7 The PASI scores of the back skin lesions of mice in groups 1 to 8 on the sixth day are shown. It can be seen that topical treatment with Preg can also effectively treat psoriasis, and the higher the dose, the better the effect.

[0079] like Figure 8 Shown are HE-stained micrographs of the back skin lesions of mice in groups 1 to 8 on the sixth day, further demonstrating that topical administration of Preg can significantly and effectively improve psoriasis skin lesions.

[0080] Example 3 Systemic administration of pregnenolone can significantly inhibit atopic dermatitis

[0081] 1. Experimental methods

[0082] Forty-eight 8-week-old female Balb / c mice were randomly divided into 8 groups (6 mice in each group):

[0083] OVX group: Under isoflurane gas anesthesia, all mice except the sham control group underwent bilateral ovariectomy to remove the ovaries.

[0084] Sham control group: underwent surgery but without oophorectomy.

[0085] Pregnenolone (Preg) was purchased from Selleck, dissolved in ethanol and further diluted in sterile water to a working concentration before use.

[0086] Atopic dermatitis modeling: 20ul of calcipotriol (MC903) / ear / day was administered to mice in the modeling group.

[0087] The treatment of mice in each group is shown in the following table:

[0088] Group No modeling Group MC903 Modeling 1 Sham operation group + sterile water injection 5 Sham operation group + sterile water injection 2 OVX group + sterile water injection 6 OVX group + sterile water injection 3 OVX low dose Preg (1 mg / kg / d) 7 OVX low dose Preg (1 mg / kg / d) 4 OVX high dose Preg (10 mg / kg / d) 8 OVX high dose Preg (10 mg / kg / d)

[0089] Groups 1 to 4 were not treated with MC903, Group 5 was a sham operation group (simultaneously injected with sterile water + applied with MC903 to establish atopic dermatitis model); Group 6 was an OVX group (simultaneously injected with sterile water + applied with MC903); Group 7 was an OVX group (simultaneously injected with low-dose Preg + applied with MC903); Group 8 was an OVX group (simultaneously injected with high-dose Preg + applied with MC903); The drugs were applied continuously for 7 to 9 days, and the thickness of the mouse ear lesions was measured every day. Then the mice were weighed and photographed, and then the mice were killed, and the ear lesions were taken for HE staining experiments to examine the thickness of the epidermis, that is, the proliferation of keratinocytes, and the spleen of the mice was weighed and photographed.

[0090] 2. Results

[0091] like Fig. 9 The pictures of the ear lesions of mice in groups 1 to 8 are shown. It can be seen that the ear lesions of the MC903 group have obvious erythema, edema, thickening, and scaling compared with the non-MC903 group, proving that the atopic dermatitis model was successfully induced. In addition, the ear lesions of the OVX+MC903 group were more severely inflamed than those of the sham surgery+MC903 group, indicating that postmenopausal sex hormone deficiency can aggravate atopic dermatitis. In the OVX+injection group, the erythema, infiltration, and thickening of the Preg injection group were significantly reduced compared with the sterile water injection group, indicating that Preg can effectively treat atopic dermatitis; in the Preg group, the high-dose Preg (10 mg / kg / d) had lighter lesion inflammation than the low-dose Preg (1 mg / kg / d), indicating that the higher the dose of Preg, the better the effect of inhibiting MC903-induced atopic dermatitis inflammation. In conclusion, systemic administration of Preg can significantly inhibit postmenopausal MC903-induced atopic dermatitis-like inflammation.

[0092] like Fig.10 The graph shows the thickness change curve of the ear skin lesions of mice in groups 1 to 8 from the first day to the ninth day. Fig.11 This is the thickness of the ear lesions of mice in groups 1 to 8 on the ninth day. It can be seen that systemic administration of Preg can effectively treat atopic dermatitis, and the higher the dose, the better the effect.

[0093] like Fig.12 Shown are HE-stained micrographs of ear lesions of mice in groups 1 to 8 on the ninth day, further demonstrating that systemic administration of Preg can effectively improve the lesions of atopic dermatitis.

[0094] Example 4 Topical administration of pregnenolone can significantly inhibit atopic dermatitis

[0095] 1. Experimental methods

[0096] Forty 8-week-old female Balb / c mice were randomly divided into 8 groups (5 mice in each group), as shown in the following table:

[0097] Group Sham operation group Group OVX group 1 Sham operation group + MC903 5 OVX group + MC903 2 Sham operation group + MC903 + BASE 6 OVX surgery set + MC903 + BASE 3 Sham operation group + MC903 + 0.5% Preg 7 OVX group+MC903+0.5%Preg 4 Sham operation group + MC903 + 1.0% Preg 8 OVX group+MC903+1.0%Preg

[0098] Pregnenolone (Preg) was purchased from Selleck Company, dissolved in ethanol, and then prepared into gel preparations with mass concentrations of 0.5% and 1.0%. The Base group was the blank matrix group.

[0099] Atopic dermatitis MC903 modeling: 20ul of calcipotriol (MC903) / ear / day was administered to the mice in the modeling group for 9 consecutive days.

[0100] Groups 1 to 4 were treated with sham surgery, and groups 5 to 8 were treated with OVX surgery. Atopic dermatitis-like dermatitis modeling began 7 weeks after surgery. In the morning, 20ul calcipotriol (MC903) was applied to the ears of groups 1 to 8. After 4 to 6 hours, blank matrix was given to groups 2 and 6, 0.5% Preg gel was given to groups 3 and 7, and 1.0% Preg gel was given to groups 4 and 8. The ear thickness was measured every day to examine the atopic dermatitis-like symptoms of mice. Then the mice were weighed and photographed, and then the mice were killed. The ear lesions were taken for HE staining experiments to examine the thickness of the epidermis and the infiltration of immune cells.

[0101] 2. Results

[0102] like Fig.13The pictures of the ear lesions of mice in groups 1 to 8 are shown. It can be seen that the MC903 group has obvious erythema, edema, scaling, and thickening, proving that the atopic dermatitis model was successfully induced. Regardless of whether OVX surgery was performed, there was no significant difference in the lesions between the MC903+external BASE group and the MC903 group, indicating that the pure gel has no significant therapeutic effect on atopic dermatitis. After adding Preg, the lesions in the MC903+Preg group improved significantly, and the higher the concentration of Preg, the better the therapeutic effect. In addition, the effect of Preg in the OVX group was more significant.

[0103] like Fig.14 Shown are the thickness graphs of ear lesions of mice in groups 1 to 8 from the first to ninth day. Fig.15 This is the thickness of the ear lesions of mice in groups 1 to 8 on the ninth day. It can be seen that topical administration of Preg can effectively treat atopic dermatitis, and the higher the dose, the better the effect.

[0104] like Fig.16 Shown are HE-stained micrographs of ear lesions of mice in groups 1 to 8 on the ninth day, further demonstrating that topical administration of Preg can effectively improve atopic dermatitis-like lesions.

[0105] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of pregnenolone as an active ingredient in the preparation of therapeutic drugs for psoriasis or atopic dermatitis.

2. A therapeutic drug for psoriasis or atopic dermatitis, characterized in that: The invention comprises pregnenolone as an active ingredient and pharmaceutically acceptable excipients.

3. The therapeutic drug according to claim 2, characterized in that The therapeutic drug is an injectable drug, an oral drug or an externally applied drug.

4. The therapeutic drug according to claim 2, characterized in that In the therapeutic drug, the mass percentage of pregnenolone is not less than 0.5%.

5. The therapeutic drug according to claim 2, characterized in that The dosage form of the therapeutic drug is injection, gel, lotion, liniment, tincture, oil, ointment, paste, patch or film.

6. The therapeutic drug according to claim 2, characterized in that The auxiliary material is selected from one or more of solvents, propellants, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, stabilizers, flavoring agents, preservatives, fragrances, penetration enhancers, pH regulators and plasticizers.

7. The therapeutic drug according to claim 6, characterized in that The solvent is selected from one or more of ethanol and physiological saline.

8. The therapeutic drug according to claim 6, characterized in that The preservative is selected from one or more of sorbic acid, methyl sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, butyl parahydroxybenzoate, benzyl parahydroxybenzoate, sodium methyl parahydroxybenzoate, benzoic acid and benzyl alcohol.

9. The therapeutic drug according to claim 6, characterized in that The emulsifier is selected from one or more of polyoxyethylene hydrogenated castor oil, hydrogenated soybean lecithin, lanolin, glyceryl stearate, sorbitan sesquioleate, cetyl alcohol, stearyl alcohol, cetearyl alcohol, castor oil and palmitate.

10. The therapeutic drug according to claim 6, characterized in that The disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone or low-substituted hydroxypropyl cellulose.

Citation Information

Patent Citations

  • Composition for treating atopic dermatitis and application thereof

    CN113952372A

  • Methods and reagents for the treatment of inflammatory disorders

    CN1901863A

  • Split dose corticosteroid therapy

    TW200902032A

  • Invasomes for therapy of disorders, their preparation and use

    US20030064948A1

  • Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments

    US20060247216A1